


FROM IDEAS TO INNOVATION

17–18 April 2024

30 Euston Square, London



**PROSTATE
CANCER UK**

We can't wait to welcome you to **FROM IDEAS TO INNOVATION!**

After reaching out to a number of our funded researchers we asked how we can best support our research community to enable you to accelerate the impact of your research, ensuring the results of your hard work have the best chance of benefiting the lives of those affected by prostate cancer.

The clear call from this insight was to provide a meeting where researchers can network, disseminate unpublished results, establish new links and explore new collaborations.

Over the two days, you'll explore a range of topics and hear from our speakers – fellow researchers and individuals with lived experiences of prostate cancer.



We're known for funding excellent researchers making an impact for men: now we're excited to host From Ideas to Innovation, our first meeting designed by and for those researchers to enable the community to share, network and collaborate.

Dr Matthew Hobbs
Director of Research, Prostate Cancer UK

Meet Prostate Cancer UK's Research team

Dr Matthew Hobbs
Director of Research



Simon Grieveson
Assistant Director of Research



Dr Julia Ambler
Head of Research Funding



Dr Hayley Luxton
Senior Research Impact & Intelligence Manager



Wesley Gilchrist
Grant Manager



Amrit Mann
Grant Manager



Krishna Kothandapani
Senior Research Officer



Debbie Peebles
Senior Research Officer



Greg Halliwell
Senior Research Impact Officer



Alex Evans
Senior Research Impact Officer

Career Acceleration Fellowships

Apply for up to £350k to support early career researchers with up to 5 years post-doctoral experience to pursue their own independent research goals. Use the funds to establish collaborations and learn new skills and techniques, becoming an independent leader in prostate cancer research.

OPEN NOW

Deadline 31 May 2024

Find out more



Scientific Organising Committee

A huge thank you to our Scientific Organising Committee, for your irreplaceable contributions towards this event:



Dr Victoria Dunne
Queen's University Belfast



Professor David Elliott
Newcastle University



**Dr Asma Ahmed
Hassan Elshiekh**
University of Glasgow



Dr Mick Brown
University of Manchester



Dr Susan Heavey
University College London



Dr Jennie Jeyapalan
University of Nottingham




From Ideas to Innovation is unique in the UK in bringing together world-leading prostate cancer researchers in an interactive environment to explore the latest advances in the field.

Dr Claire Fletcher, Imperial College London



Dr Claire Fletcher
Imperial College London



Dr Alan McWilliam
University of Manchester




Professor Paula Mendes
University of Birmingham



Dr Emma Scott
Newcastle University




Professor Charlotte Bevan
Imperial College London



Dr Ning Wang
University of Leicester



Dr Jason Webber
Swansea University



From Ideas to Innovation will invigorate the community and update on developments taking place across the many specialist fields of those working to improve care for men with prostate cancer.

Professor Greg Shaw,
University College London



Dr Greg Shaw
University College London

FINDINGS FROM THE NATIONAL PROSTATE CANCER AUDIT

Dr Matthew Hobbs will open the meeting before handing over to Chiara de Biase who will highlight Prostate Cancer UK's journey with the National Prostate Cancer Audit. Professor Noel Clarke will discuss the most recent report, including access to novel therapies. Professor Jan van de Meulen will discuss the challenges of real world data.

CHAIR

Dr Matthew Hobbs, Director of Research, Prostate Cancer UK

Dr Matthew Hobbs is responsible for overseeing our ambitious research strategy and making sure that we fund the research with the best chance of making a difference for men.



Chiara de Biase, Director of Support & Influencing, Prostate Cancer UK

Chiara de Biase oversees all the charity's activity for direct services to men and their families and the clinical community; health information, clinical education, policy and health influencing, health inequalities, Specialist Nurses and cancer data specialists.



Professor Jan van der Meulen, Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine

Professor Jan van de Meulen's main fields of interest are the application of epidemiological, statistical, and decision-analytical techniques to study effectiveness and quality of care in the areas of surgery, cancer, obstetrics and gynaecology, using electronic health records. Professor van der Meulen is Chair of the Project Teams of the National Prostate Cancer Audit and will discuss the challenges of working with real world data.

FINDINGS FROM THE NATIONAL PROSTATE CANCER AUDIT

Continued...

Professor Noel Clarke, Consultant Urological Surgeon, The Christie and Salford Royal Hospitals Manchester and Honorary Professor of Urological Oncology, The University of Manchester



Professor Noel Clarke is a Consultant Urological Surgeon and Clinician Scientist. Professor Clarke manages complex urological cancer surgery and plans and coordinates studies in urological cancer through translational science and clinical trials. In prostate cancer research and treatment he leads the GU research and FASTMAN prostate cancer research teams at The Christie / University of Manchester Cancer Research Institute. He is the joint clinical lead for the National Prostate Cancer Audit in England and Wales.



From Ideas to Innovation will unite clinicians, scientists, Prostate Cancer UK, and patient representatives in their tireless collaboration to light the path to progress and hope.

Dr Ning Wang, University of Leicester

TRANSFORMATIONAL IMPACT AWARDS

Providing funding of up to £2m to collaborative teams to deliver clinical trials or programmes of research that will significantly transform our understanding of prostate cancer and how we diagnose and treat it.

Next round opens 18 June 2024

[Click here for more info](#)



PROSTATE CANCER RISK

This session explores a man's risk of prostate cancer from a range of perspectives with topics including genetic risk, the microbiome, and the microenvironment. The session features short talks from speakers and ends in an exciting discussion where the panel will continue along this theme and answer questions from the audience.

CO-CHAIR

**Dr Jane Shortall, University of Manchester
Prostate Cancer UK Career Acceleration Fellow**

Dr Jane Shortall is currently developing risk stratification models based on a man's anatomy, biological make-up, and response to treatment over time, with the aim of moving towards more personalised treatment for all prostate cancer patients.



CO-CHAIR

Emeka Ojimba

In October 2017, Emeka's dad, Nnamdi Ojimba, was diagnosed with terminal prostate cancer after he went to the doctor due to spotting blood in his urine. He sadly passed away in 2020 at 69 years old. Emeka now campaigns with his two sisters via an organisation called Prostate Cancer Black Men (PCBM) to encourage conversations around prostate cancer, in the Black community especially and amongst a younger demographic - to support prevention and early detection.



**Dr Tanimola Martins, Senior Research Fellow and Lecturer
in Postgraduate Education, University of Exeter**

Dr Tanimola Martins has a background in Clinical Rehabilitation and Public Health and holds a PhD in ethnic inequality in the diagnosis of symptomatic cancer. His workstream aims to identify and quantify sociodemographic differences in primary care diagnosis of cancer, with the intention of formulating appropriate interventions to address such inequalities.



PROSTATE CANCER RISK

Continued...

Dr Jana McHugh, Clinical Research Fellow in Oncogenetics, The Institute of Cancer Research and Senior Registrar, The Royal Marsden

Dr Jana McHugh works with Professor Ros Eeles at the Institute of Cancer Research in prostate cancer and the genetics associated with it. She works with the Oncogenetics team on the role of genetic variation in increased prostate cancer risk.



Professor Dan Brewer, Professor in Medical Bioinformatics and Genomics, University of East Anglia

Professor Dan Brewer is a group leader within the Cancer Genetics Team, Norwich Medical School, with over a decade of experience in applying and developing novel analyses of large-scale 'omics datasets from human tumour samples with a focus on improving clinical outcomes in prostate cancer.



Dr Abraham Gihawi, Prostate Cancer UK Career Acceleration Fellow, University of East Anglia

Dr Abraham Gihawi investigates the link between bacteria and aggressive prostate cancer. His recent project focuses on looking for evidence of novel bacteria and aggressive disease with a focus on aggressive prostate cancer in men of African ancestry.



Dr Claire Fletcher, Advanced Research Fellow, Imperial College London

Obesity is associated with increased risk of aggressive prostate cancer and reduced therapy response. Dr Claire Fletcher's research aims to understand the underlying mechanisms of this by investigating the bi-directional communication between prostate cancer cells and their surrounding adipose tissue.



EARLY DIAGNOSIS

This session looks to deliver lightning talks following a man's journey through the current diagnostic pathway. These will cover topics including developing novel diagnostic tests, concepts of screening, and emerging AI and imaging technologies. It will conclude with a fireside chat involving all listed speakers. This session will heavily feature the perspective of lived experience throughout the talks and discussion.

CO-CHAIR

Dr Jennie Jeyapalan, Assistant Professor in Cancer Biology, University of Nottingham

Dr Jennie Jeyapalan's research focus is on epigenetic reprogramming in cancer progression and treatment resistance. Her group uses bioinformatics, cell models and molecular biology techniques to identify new therapeutic targets for advanced prostate cancer.



CO-CHAIR

Paul Dennington

In February 2021 Paul was diagnosed with prostate cancer. At first he was diagnosed with locally advanced prostate cancer, however a month later after further scans, Paul was diagnosed with incurable cancer. Paul is now dedicated to raising awareness of the disease and has fundraised £71,000 for Prostate Cancer UK, organising many events including a 25 million step challenge.



Dr Tristan Barrett, Associate Professor in Radiology and Honorary Consultant Radiologist, University of Cambridge

Dr Tristan Barrett is clinical lead for uro-radiology at Cambridge University Hospitals, and his main research interest is in prostate cancer, with a particular interest in MRI techniques for identifying and characterising prostate tumours.



EARLY DIAGNOSIS

Continued...

Professor Paula Mendes, Professor of Advanced Materials and Nanotechnology, University of Birmingham

Professor Paula Mendes works at the interface between engineering, chemistry, and biology. Having completed her PhD at the University of Porto, Portugal, before continuing her training in France, UK and USA, Paula established her group at the University of Birmingham in 2006.

Prostate Cancer UK has supported Paula since 2017 on a project looking to use sugars to diagnose aggressive prostate cancer.



Dr Veeru Kasivisvanathan, Associate Professor and Consultant Surgeon, University College London and University College London Hospitals

Dr Veeru Kasivisvanathan will be presenting the late breaking results of the PRIME study, which will establish whether a shorter, more streamlined biparametric MRI can become the new standard of care for prostate cancer diagnosis.



Professor Shonit Punwani, Professor of Magnetic Resonance and Cancer Imaging, Consultant Radiologist and Head of the Centre for Medical Imaging, University College London and University College London Hospitals

Professor Shonit Punwani is the Chair of the National Cancer Imaging Translational Accelerator. He focuses on advancing and implementing new MRI techniques for prostate cancer screening and management, and investigates in-vivo prostate cancer metabolism as an indicator of aggressive disease and its use as a tool to guide treatment decisions.



PROSTATE CANCER UK MENTORING SCHEME

Our mentoring scheme aims to support early career researchers at the start of their prostate cancer research careers. We're looking for mentees who have clear objectives they'd like to meet and mentors with a willingness to share their experiences.

Want to find out more?


Ask a member of the research team or email research@prostatecanceruk.org



DAY 1: WEDNESDAY 17 APRIL 2PM-2:30PM

SUPPORT FROM PROSTATE CANCER UK

Simon Grieveson and Hayley Luxton will highlight ways in which Prostate Cancer UK can support you and your research, from making introductions, our open access reimbursement scheme and helping to disseminate your research.



PROGNOSIS

This session aims to explore prognosis following a man's journey through prostate cancer and how the speakers' respective works explore this. Topics include extracellular vesicles, circulating tumour cells, medical physics, and lymphatic spread. This will be wrapped up with a discussion exploring key points and addressing audience questions.

CO-CHAIR

Dr Corrine Woodcock, Prostate Cancer UK Career Acceleration Fellow, University of Nottingham

Dr Corrine Woodcock is studying how prostate cancer cells can utilise and adapt RNA methylation to develop resistance to existing prostate cancer treatments. She will use inhibitors to study whether resistance to existing prostate cancer treatments such as enzalutamide can be prevented, reversed, or delayed, with the goal of extending the duration and quality of life for men with prostate cancer.



CO-CHAIR

Gary Reeves

Gary was told he had an aggressive form of prostate cancer with a Gleason score of 7 (4+3), but was at the T2 stage. This was later upgraded to T3 after his prostate was removed and examined, as the cancer had started to head towards his bowel and bladder. He had successful surgery to remove his prostate (robotically) and is still going strong nearly 8 years later.



Professor Hing Leung, Professor of Urology and Surgical Oncology and Director of Innovation, Engagement and Enterprise, University of Glasgow

Professor Hing Leung has a longstanding interest in applying new knowledge of prostate cancer biology to design novel treatment strategies, focusing on treatment resistance and cancer progression. Professor Hing will present ongoing research on biomarkers and actionable therapeutic targets.



PROGNOSIS

Continued...

Dr Jason Webber, Senior Lecturer, and co-lead for the Advanced Diagnostics & Medical Technologies Research Institute, Swansea University

Dr Jason Webber's research interest is cellular communication within the tumour microenvironment, with a focus on extracellular vesicles, and development of novel biomarkers for early detection of aggressive prostate cancer.



Professor Yong-Jie Lu, Professor of Medical Oncology, Queen Mary University of London

Professor Yong-Jie Lu develops circulating biomarkers, with a focus on circulating tumour cells, which are prognostic for prostate cancer either diagnosed at early stage or during therapy for optimised treatment stratification.



Dr Alan McWilliam, Senior Lecturer in Translational Radiotherapy Physics, University of Manchester

Dr Alan McWilliam's research focuses on (1) developing methodologies to data mine the radiotherapy dose directly, aiming to uncover hidden associations with anatomical sub-regions and patient outcomes; (2) develop image-based biomarkers to aid with treatment personalisation and risk stratification.



Dr Ashwin Sachdeva, NIHR Academic Clinical Lecturer in Urology, University of Manchester and The Christie Hospital

Dr Ashwin Sachdeva focuses on imaging biomarkers within the STAMPEDE trial, evaluating long-term toxicity of therapies using routinely collected health data, and development of AI-driven spatial infrared spectroscopy.



LOCALISED PROSTATE CANCER

This session takes us on a journey from 'bedside to bench'. Talks will cover a range of topics including obtaining samples and promoting inclusivity in prostate cancer research, radiotherapy, heterogeneity in localised disease, as well as models to advance drug testing and personalised medicine. This session will wrap up with an open discussion that looks to the future and where the field goes next.

CO-CHAIR

Professor David Elliott, Professor of Genetics, Newcastle University

Professor David Elliott investigates gene expression control in prostate cancer, and how this is regulated at the level of splicing.



CO-CHAIR

Robert Dimmick

Ex-Mayor of Reading, Robert, heard about the death of Bill Turnbull a few weeks before his 75th birthday and thought he had better check up on what the symptoms of prostate cancer are. He started hormone therapy and radiotherapy and is continuing hormone therapy. Robert is now doing well and is part of a local prostate cancer support group.



Professor Greg Shaw, Professor of Urology and Consultant Urologist, University College London

Professor Greg Shaw will talk about the buddy scheme to support African and Caribbean men in treatment decision making for prostate cancer and involvement in research. Professor Shaw is lead for robotic Urology at University College London Hospital, the biggest radical prostatectomy centre in the UK and Professor of Urology at University College London.



LOCALISED PROSTATE CANCER

Continued...

Professor Suneil Jain, Professor of Clinical Oncology, Queen's University Belfast and Consultant Clinical Oncologist, Northern Ireland Cancer Centre

Professor Suneil Jain's research interests include stereotactic radiotherapy in high-risk prostate cancer and he is Chief Investigator on two ongoing international phase III clinical trials.



Professor Rob Bristow, Director of Manchester Cancer Research Centre and Honorary Consultant, University of Manchester

Professor Rob Bristow will discuss intra- and inter-tumoural genetic and microenvironment prognostic factors that address the relative aggression of high-risk and locally advanced prostate cancer. This will include an update of BRCA2 and ATM hereditary prostate cancer and the development of novel human models to interrogate the effect on progression based on somatic versus germline loss of function of these genes.



Professor Ian Mills, John Black Professor of Prostate Cancer, University of Oxford and Professor of Translational Prostate Cancer Biology, Queen's University Belfast

Professor Ian Mills' research interests include identifying transcriptional and metabolic drivers of prostate cancer progression and defining molecular changes that support the emergence of treatment resistance.



LOCALISED PROSTATE CANCER

Continued...

Dr Anastasia Hepburn, Prostate Cancer Foundation Young Investigator, Newcastle University



Dr Adriana Buskin, Prostate Cancer UK Career Acceleration Fellow, NC3Rs Training Fellow, Newcastle University



Dr Anastasia Hepburn and Dr Adriana Buskin will discuss developing an induced pluripotent stem cell-derived prostate organoid model to study prostate cancer disease and to advance drug testing and personalised medicine.

When this session concludes at 5pm please join us in the atrium for a drinks reception. Take this opportunity to view posters, network and celebrate your work!

SIGN UP TO OUR NEWSLETTER

Want to stay in the know? Sign up to our bi-monthly Research Newsletter for the latest updates on funding rounds, meetings and ways we can support you and your research!



Sign up today!




RESEARCH INNOVATION AWARDS

Funding the boldest, brightest and most innovative projects in prostate cancer research. Covering fundamental and clinical research (and all stages in between), we're looking to support research that has real potential to significantly impact the way prostate cancer is diagnosed and treated.

NEXT ROUND OPENS 23 JULY 2024

Find out more



METASTATIC PROSTATE CANCER

This session will feature researchers taking varied approaches to enhance the prognosis and treatment of metastatic disease, including research focused on improving radiotherapy, assessment of treatment response and recurrence risk, and mechanisms of bone metastasis. To finish the session, a Q+A will allow participants to reflect on challenges and hopes for the treatment of metastatic disease.

CO-CHAIR

Dr Demi Pritchard, Postdoctoral Researcher, Swansea University

Dr Demi Pritchard is a member of the Extracellular Vesicle Biology Research Group with Dr Jason Webber at Swansea University. This position focuses on prostate cancer and its early detection using extracellular vesicles as a blood-based biomarker.



CO-CHAIR

Martin Wells

Martin was diagnosed with localised prostate cancer in 2007. He initially underwent surgery to remove the prostate, then had radiotherapy and hormone suppression therapy. Ten years later, Martin discovered the cancer had reignited in his bones, for which he is undergoing lifelong treatment to manage.



Professor Jayne Tierney, Professor of Evidence Synthesis and co-lead for Meta-analysis Programme at MRC Clinical Trials Unit, University College London

Professor Jayne Tierney's team systematically reviews results and data from clinical trials worldwide, to evaluate the effects of therapies for cancers and other conditions. As principal investigator for the STOPCAP programme of reviews, Professor Tierney has led research to assess the effects of treatments for advanced prostate cancer. Currently, this includes assessing whether docetaxel or androgen receptor signalling inhibitors such as abiraterone or enzalutamide are most effective and for which men.



METASTATIC PROSTATE CANCER

Continued...

Dr Claire Vale, Principal Research Fellow in MRC Clinical Trials Unit, University College London

Dr Claire Vale has been key to developing and delivering systematic reviews to evaluate effects of treatments for advanced prostate cancer including docetaxel, androgen receptor signalling inhibitors and prostate radiotherapy through the STOPCAP programme. Dr Vale is currently developing research to ensure that more men with advanced prostate cancer receive the most effective treatments.



Professor Gert Attard, John Black Charitable Foundation Endowed Chair in Urological Cancer Research and Honorary Medical Oncology Consultant, University College London

Professor Gert Attard is an academic medical oncologist specialising in the treatment of advanced prostate cancer. Professor Attard's research focuses on treatment resistance and explaining the highly variable disease course. His work is implemented in and leverages prospective clinical trials, including STAMPEDE, PARADIGM and RE-IMAGINE.



DISSEMINATING YOUR RESEARCH

Follow us on X (formerly twitter) through our Professional Support channel **@ProstateUKProfs** to be amongst the first to know about articles published from Prostate Cancer UK funded researchers.



As part of our coffee club tweets we highlight a recently published paper, encourage you to grab a coffee (or your favourite beverage) and click on the link to read the paper.

Stay in the loop, share your thoughts, and be part of the conversation!



METASTATIC PROSTATE CANCER

Continued...

Dr Alison Tree, Uro-oncology Clinical Trials Group Leader and Consultant Clinical Oncologist, The Institute of Cancer Research

Dr Alison Tree's research focuses on making radiotherapy more effective at curing prostate cancer whilst also reducing side effects. Dr Tree also conducts research into the role of radiotherapy in metastatic prostate cancer, including the Prostate Cancer UK-funded TRAP trial.



Dr Julia Murray, Group Leader and Consultant Clinical Oncologist, The Institute of Cancer Research

Dr Julia Murray's research interests include evaluating radiotherapy technology in patients with advanced prostate cancer. Dr Murray will discuss the STAR-TRAP study which is assessing the role of stereotactic radiotherapy in men with metastatic prostate cancer on first line systemic therapy.




Professor Emma Hall, Professor of Oncology Trials and Co- Director of the Clinical Trials and Statistics Unit, The Institute of Cancer Research

Professor Emma Hall is a trials methodologist/clinical trial statistician with experience in the design, methodology and analysis of prostate cancer clinical trials and a particular interest in radiotherapy research.



Dr Ning Wang, Research Fellow, University of Leicester

Dr Ning Wang specialises in targeting glucose metabolism in prostate cancer initiation and metastasis, particularly focusing on pre-clinical models for bone metastasis. Additionally, his research explores innovative strategies, such as incorporating exercise, to prevent metastasis in prostate cancer.



OVERCOMING TREATMENT RESISTANCE

This session will feature researchers characterising mechanisms of resistance to prostate cancer therapies, and developing new ways of overcoming them. This includes overcoming castrate resistance and explores the role of the immune system and novel immunotherapies. The session will finish with a discussion to address key questions in the field.

CO-CHAIR

Dr Susan Heavey, Prostate Cancer UK Travel Prize Fellow, Lecturer in Translational Medicine, University College London

Dr Susan Heavey is interested in the use of 3D ex vivo models to predict treatment responses in cancer. Her project, Radio3D, is investigating radioresistant prostate cancer in both pre and post radiotherapy groups and novel 3D in vitro models.



CO-CHAIR

Tony Collier, BEM

Tony was diagnosed with terminal prostate cancer when he was 60 years old in May 2017. He underwent hormone-suppressing injections and was meant to start chemotherapy shortly after his diagnosis. However after hearing about the effectiveness of abiraterone following an announcement at ASCO, Tony's oncologist persuaded his private medical insurers to fund this treatment instead. Tony did experience some initial liver function problems, but they thankfully normalised and he has remained on a half dose of abiraterone ever since.



Professor Charlotte Bevan, Professor of Cancer Biology, Imperial College London

Professor Charlotte Bevan's research is focused on mechanisms of androgen signalling, mechanisms of escape from hormonal control of prostate tumours, and new approaches to inhibit androgen signalling in resistant disease. She is exploring convergence science approaches to addressing therapy resistance, in collaboration with colleagues in the physical sciences.



OVERCOMING TREATMENT RESISTANCE

Continued...

Professor Jason Carroll, Professor of Molecular Oncology, Cancer Research UK Cambridge Institute, University of Cambridge

Professor Jason Carroll explores transcription factor networks to improve prostate cancer outcomes. Professor Carroll will be discussing the role of pioneer and master transcription factors in prostate cancer.



Professor Johann de Bono, Regius Professor of Cancer Research and Professor in Experimental Cancer Medicine, The Institute of Cancer Research

Professor Johann de Bono's work focuses on identifying and pursuing treatment strategies that can improve outcomes from aggressive prostate cancers.



Dr Emma Scott, Prostate Cancer UK Travelling Prize Fellow, Newcastle University

Dr Emma Scott's research is investigating the role of glycan-binding proteins in modulating the immunosuppressive functions of myeloid cells in prostate cancer.



Professor Eileen Parkes, Associate Professor of Innate Tumour Immunology and Consultant Medical Oncologist, University of Oxford

Professor Eileen Parkes has a research focus on early phase trials using novel immunotherapies and overcoming treatment resistance. Professor Parkes will talk about her work focusing on the prostate immune microenvironment.



NOVEL THERAPIES

This session will address the development of innovative new treatments for prostate cancer. We will hear short talks from researchers who are taking various approaches to identify new therapeutic targets and take them towards the clinic. We will finish with a discussion addressing key questions and challenges in the development of new therapies.

CO-CHAIR

Dr Simon McDade, Reader and Group Leader, Queen's University Belfast

Dr Simon McDade's functional genomics lab focuses on a wide-range of genomic technologies and integrative data analysis to identify novel vulnerabilities that can be exploited to improve cancer patient outcomes. Dr McDade is the academic lead of Queen's University Belfast genomics core and co-founder of two genomics-driven spin outs: AilseVax, a cancer vaccine technology company, and BlokBio, a software company building intelligent genomics workflows.



CO-CHAIR

Gary Hooker

Gary discovered he had advanced prostate cancer at 55 in January 2011. He was given a prognosis of 18 months to two years. Gary started treatment straight away and eventually was put on a clinical trial, Enzalutamide, which he has been on for ten years, outlasting his prognosis. Gary is the longest person in the world to be on the drug. Gary is very fit and has taken part in many challenges. However, in November 2020, he recently found out that his PSA levels have doubled.



Professor Simon MacKay, Professor of Medicinal Chemistry, University of Strathclyde

Professor Simon MacKay has 30 years' experience of research in drug discovery and development, primarily in cancer. Professor MacKay is the Principle Investigator on the IKK α -focused drug discovery programme which has been funded by Cancer Research UK and Prostate Cancer UK and generated two patents covering the first-in-class inhibitor series.



NOVEL THERAPIES

Continued...

Professor Helen McCarthy, Chair of Nanomedicine, Queen's University Belfast

Professor Helen McCarthy focuses on using natural peptides to deliver nucleic acids such as mRNA intracellularly without detection. As a named inventor on 17 patents and founder of a spin-out company in 2017, Professor McCarthy's technology is being translated towards the clinic for a range of oncology indications including prostate cancer.



Professor Jonathan Coulter, Professor of Pharmaceutical Nanoscience, Queen's University Belfast

Professor Jonathan Coulter focuses on developing novel nanotherapeutic approaches to increase the effectiveness of radiotherapy while limiting damage to surrounding normal tissue. Professor Coulter also serves as Director and Chief Technical Officer of BXTA Nanotherapy, a joint venture company seeking to translate a lead candidate nanoparticle formulation to first-in-human studies and commercialisation.



Professor Valentine Macaulay, Emeritus Associate Professor and Honorary Consultant in Medical Oncology, University of Oxford

Professor Valentine Macaulay investigates the contribution of insulin growth factors to cancer biology, aiming to use this information to improve the management of men with prostate cancer.



Dr Clare Verrill, Associate Professor of Cellular Pathology, University of Oxford

Dr Clare Verrill is a pathologist with a particular focus on utilising digital pathology and artificial intelligence to generate novel insights into the biology of cancer. She is a key collaborator on the Prostate Cancer UK funded WINGMEN trial, which is investigating the role and therapeutic potential of IGF-1-targeted antibody xentuzumab.




NETWORKING SESSIONS

Join us for a networking session, where we'll break out into smaller discussion groups to unpick a particular topic. We'll be discussing:

- Big data and artificial intelligence
- Diversity in research
- Collaborating with industry
- Prostate cancer models
- Maximising funding applications

This is a unique opportunity to build connections with other researchers whilst brainstorming key challenges faced by prostate cancer researchers.



MRC CLINICAL RESEARCH TRAINING FELLOWSHIPS

These grants, jointly funded with the Medical Research Council, support healthcare professionals to do a PhD or reacquire research skills. Funds can cover salary, tuition fees and research costs of up to £25k, for three years.

Next round opens early June 2024

Find out more



FUTURE DIRECTIONS

*30 minute coffee break at 3:30pm

The final session of From Ideas to Innovation will see Prostate Cancer UK funded early career researchers focusing on the big questions that need to be addressed by the prostate cancer research field. This session sees early career researchers from diverse fields come together to give a united vision of the future in an extended discussion and question and answer session.

CO-CHAIR

Dr Kelly Coffey, Group Leader in Cell Signalling, Newcastle University

Dr Kelly Coffey held a Prostate Cancer UK Career Development Fellowship and sits on our advisory panel for our Career Acceleration Fellowships. Dr Coffey's research focuses on the molecular mechanisms of prostate cancer development and progression, to identify signalling pathways that could be targeted by novel prostate cancer treatments.



CO-CHAIR

Dr Patrick Williams

Patrick was first diagnosed with stage 4 prostate cancer in 2019 at just 63 years old. He was given 18 months to 2 years to live. Patrick started hormone therapy, along with 6 cycles of chemotherapy. Initially these treatments went well, and Patrick's PSA declined rapidly. All of this started in January 2020. Two weeks after he started three monthly injections, his PSA levels started to drop again.



Dr Abraham Gihawi, Prostate Cancer UK Career Acceleration Fellow, University of East Anglia

Dr Abraham Gihawi investigates the link between bacteria and aggressive prostate cancer. His recent project focuses on looking for evidence of novel bacteria and aggressive disease with a focus on aggressive prostate cancer in men of African ancestry.



FUTURE DIRECTIONS

Continued...


Dr Rachel Barker, Prostate Cancer UK Career Acceleration Fellow, University of Bristol

Dr Rachel Barker is interested in the processing of amyloid precursor protein, an enzymatic pathway that is important in Alzheimer's disease, and investigating its contribution to prostate cancer risk, development and progression. Understanding its role in prostate cancer may help to identify new targets for treatment, many of which have already had drugs developed for Alzheimer's disease therapy.



Dr Juan Manuel Jiménez Vacas, Prostate Cancer UK Career Acceleration Fellow, The Institute of Cancer Research

Dr Juan Jiménez Vacas focuses on unveiling vulnerabilities that arise in response to androgen receptor signalling inhibitors in advanced prostate cancer, with the ultimate goal of developing novel and effective therapeutic strategies for combating this aggressive disease.



Dr Joe Taylor, Prostate Cancer UK Career Acceleration Fellow, The Institute of Cancer Research

Dr Joe Taylor studies post-transcriptional mechanisms to develop novel strategies to treat lethal prostate cancer. His current Prostate Cancer UK Career Acceleration Fellowship is investigating the function and therapeutic vulnerability of PDCD4, a negative regulator of mRNA translation, in lethal prostate cancer.



FUTURE DIRECTIONS

Continued...


Dr Emma Scott, Prostate Cancer UK Travel Prize Fellow, Newcastle University

Dr Emma Scott studies myeloid expressed Siglec receptors as new immunotherapeutic targets for prostate cancer.



Dr Asma Ahmed Hassan Elshiekh, Prostate Cancer UK Career Acceleration Fellow, Cancer Research UK Scotland Institute

Dr Asma Ahmed Hassan Elshiekh aims to understand the underlying mechanisms of immunogenic cell death as a novel treatment for advanced prostate cancer to improve therapy and sensitise prostate cancer to immunotherapy.



Dr Victoria Dunne, Prostate Cancer UK Career Acceleration Fellow, Queen's University Belfast

Dr Victoria Dunne's research focuses on developing novel treatments for men with metastatic castration-resistant prostate cancer. These treatments involve the use of radionuclides including radium-223, actinium-225 and lead-212 and combining these alpha particles with DNA damage response inhibitors and immune checkpoint inhibitors.



Dr Edward O'Neill, Prostate Cancer UK Career Acceleration Fellow, University of Oxford

Every man's journey with prostate cancer is unique and so is their prostate cancer's response to radionuclide therapy. Dr Edward O'Neill's research focuses on tailoring radionuclide drug combinations with PET imaging to prevent recurrence and overcome radioresistance.




MAKING PROGRESS

Making Progress will be back in April 2025!

Making Progress is a meeting dedicated to the development of early career researchers working in prostate cancer research.

Sign up to our newsletter to keep up to date with Making Progress and other research related news.

Sign up here!



STARTER GRANTS FOR CLINICAL LECTURERS

We are partnering with the Academy of Medical Sciences on their Starter Grants scheme to support research-active clinical lecturers. The grants provide funding for consumables as well as access to extra support through the academy.

Next round opens in July 2024

Find out more



AREAS OF KNOWLEDGE WITHIN OUR FUNDED RESEARCHERS

Based on information submitted as part of the registration form we've listed areas of knowledge among our funded researchers on the following pages. We encourage you to use this as a tool to find and reach out to new potential collaborators!

*We have done our best to provide accurate information & job titles, our sincerest apologies if anything is incorrect.

Models of prostate cancer (including 3D cultures, 3D models, animal models, artificial cells, cell culture, drug resistance, ex vivo, stem cells)

Mr Vithurran Thavarajah
University College London

Dr Rachel McCole
Queen's University Belfast

Dr Emma Scott
Newcastle University

Dr Susan Heavey
University College London

Dr Damien Leach
Imperial College London

Dr Adriana Buskin
Newcastle University

Miss Katarzyna Peszko
Imperial College London

Dr Richa Vasani
University of Glasgow

Dr Esther Baena
CRUK Manchester Institute

Mr Eduardo Mota
University College London

Dr Paris Avgoustou
University of Sheffield

Dr Edward O'Neill
University of Oxford

Dr Uzoamaka Okoli
University College London

Professor Hing Leung
University of Glasgow

Professor Craig Robson
Newcastle University

Dr Ning Wang
University of Leicester

Professor Karen Blyth
CRUK Scotland Institute

Dr Asma Ahmed
University of Glasgow

Mr Nicolas Zeitouni
Imperial College London

Dr Kirsteen Campbell
CRUK Scotland Institute

Dr Nil Grunberg
Imperial College London

Dr Rachel Barker
University of Bristol

Professor Imran Ahmad
University of Glasgow

Mr George Bryant
The Open University

Dr Marco Bezzi
Institute of Cancer Research

Omics (including genomics, epigenomics, epitranscriptomics, genome organisation, spatial transcriptomics)

Professor Yong-Jie Lu
Queen Mary University of
London

Miss Dhruvika Varun
University of Nottingham

Dr Corinne Woodcock
University of Nottingham

Dr Francesco Crea
The Open University

Miss Anna Harris
University of Nottingham

Dr Simon McDade
Queen's University Belfast

Dr Kayleigh Orchard
The Open University

Dr Rayzel Fernandes
Imperial College London

Dr Rachel McCole
Queen's University Belfast

Miss Denisa Bogdan
Institute of Cancer Research

Mr Rodhan Patke
University of Nottingham

Professor Simak Ali
Imperial College London

Miss Rachel Thompson
University of Nottingham

Dr Srinivasa Rao
University of Oxford

Omics (including genomics, epigenomics, epitranscriptomics, genome organisation, spatial transcriptomics) continued...

Professor Moray Campbell
Cedars-Sinai Medical Center

Professor Daniel Brewer
University of East Anglia

Professor Jason Carroll
University of Cambridge

Dr George Seed
The Institute of Cancer
Research

Dr Jana McHugh
The Institute of Cancer
Research

Mr Qi Wang
CRUK Scotland Institute

Professor Prabhakar Rajan
Queen Mary University of
London

Professor Robert Bristow
Manchester Cancer
Research Centre

Miss Jinseon Kim
University of Oxford

Dr Susan Heavey
University College London

Dr Jennie Jeyapalan
University of Nottingham

Dr Esther Baena
CRUK Manchester Institute

Dr Sara Luzzi
Newcastle University

Dr Uzoamaka Okoli
University College London

Cell biology

Dr Greg Brooke
University of Essex

Dr Hanieh Montaseri
Imperial College London

Dr Jun Ishihara
Imperial College London

Dr Mark Linch
University College London

Dr Valentine Macaulay
University of Oxford

Molecular biology

Mr Rodhan Patke
University of Nottingham

Dr Joe Taylor
The Institute of Cancer
Research

Dr Conrado Guerrero Quiles
The University of
Manchester

Miss Rachel Thompson
University of Nottingham

Mr Vithurran Thavarajah
University College London

Dr Corinne Woodcock
University of Nottingham

Dr Richa Vasan
University of Glasgow

Dr Haiyan An
Swansea University

Dr Chun Fui Lai
Imperial College London

Dr Sara Luzzi
Newcastle University

Dr Demi Pritchard
Swansea University

Professor Simak Ali
Imperial College London

Dr Greg Brooke
University of Essex

Miss Dhruvika Varun
University of Nottingham

Mr Zu Ming Ng
Imperial College London

Miss Hanna Mohamed
University College London
Cancer Institute

Professor Prabhakar Rajan
Queen Mary University of
London

Professor David Elliott
Newcastle University

Dr Daniel Turnham
Cardiff University

Miss Anna Harris
University of Nottingham

Dr Juan M Jiménez Vacas
The Institute of Cancer
Research

Molecular biology

Professor Ian Mills
University of Oxford

Professor Hing Leung
University of Glasgow

Miss Poppy Brown
CRUK Scotland Institute

Dr Laura Martinez Escardo
CRUK Scotland Institute

Ms Maggie Orozco Moreno
Newcastle University

Miss Xinwei Zhou
Imperial College London

Dr Zoe Maylin
Vancouver Prostate Centre

Professor Craig Robson
Newcastle University

Miss Katarzyna Peszko
Imperial College London

Dr Kirsty Hodgson
Newcastle University

Miss Jinseon Kim
University of Oxford

Dr Kirsteen Campbell
CRUK Scotland Institute

Dr Marco Bezzi
The Institute of Cancer
Research

Dr Victoria Dunne
Queen's University Belfast

Dr Edward O'Neill
University of Oxford

Professor Imran Ahmad
University of Glasgow

Professor Gert Attard
University College London

Dr Jennie Jeyapalan
University of Nottingham

Dr Kelly Coffey
Newcastle University

Dr Jason Webber
Swansea University

Androgen receptor biology (androgen receptor, androgen signalling, androgen receptor inhibitors)

Dr Adam Sharp
The Institute of Cancer
Research

Dr Damien Leach
Imperial College London

Miss Wanting Zeng
The Institute of Cancer
Research

Professor Gert Attard
University College London

Professor Nigel Mongan
University of Nottingham

Miss Anna Harris
University of Nottingham

Professor Charlotte Bevan
Imperial College London

Dr Zoe Maylin
Vancouver Prostate Centre

Dr Corinne Woodcock
University of Nottingham

Dr Greg Brooke
University of Essex

Professor Craig Robson
Newcastle University

Professor Hardev Pandha
University of Surrey

Miss Xinwei Zhou
Imperial College London

Extracellular (vesicles, matrix, fibroblasts)

Dr Matthew Blakeley
Imperial College London

Dr Haiyan An
Swansea University

Miss Jessica Willis
Swansea University

Miss Katarzyna Peszko
Imperial College London

Miss Jessica Willis
Swansea University

Dr Nil Grunberg
Imperial College London

Dr Demi Pritchard
Swansea University

Dr Jason Webber
Swansea University

Molecular techniques and analysis (microscopy, flow cytometry, hyperion)

Dr Ed Roberts
CRUK Scotland Institute

Dr Emma Lishman-Walker
Newcastle University

Dr Andrea Mohr
University of Essex

Cell signalling (CDK inhibitors, G-coupled receptors, protein engineering)

Ms Ellen Olden
Imperial College London

Dr Emma Lishman-Walker
Newcastle University

Dr Robert Kypta
Imperial College London

Dr Chun Fui Lai
Imperial College London

Dr Laura Martinez Escardo
CRUK Scotland Institute

Dr Benjamin Schumann
Francis Crick Institute

Dr Helen Pearson
Cardiff University

Dr Paris Avgoustou
University Of Sheffield

Professor Simak Ali
Imperial College London

Glycobiology (glycans, glycosylation)

Miss Ziqian Peng
Newcastle University

Dr Emma Scott
Newcastle University

Dr Benjamin Schumann
Francis Crick Institute

Ms Maggie Orozco Moreno
Newcastle University

Professor Paula Mendes
University of Birmingham

Dr Kirsty Hodgson
Newcastle University

Metabolism

Dr Mick Brown
The University of
Manchester

Miss Yuhan Zhou
The University of Sheffield

Dr Ashwin Sachdeva
The University of
Manchester

Dr Nikita Sushentsev
University of Cambridge

Microbiota

Dr Miguel Reis Ferreira
King's College London

Tumour microenvironment

Dr Abraham Gihawi
University of East Anglia

Dr Conrado Guerrero Quiles
The University of Manchester

Dr Ameera Jailani
University of Sheffield

Mr Kyle Greenland
Imperial College London

Dr Helen Pearson
Cardiff University

Dr Nil Grunberg
Imperial College London

Dr Eileen Parkes
University of Oxford

Professor Jonathan Coulter
Queen's University Belfast

Dr Claire Fletcher
Imperial College London

Dr Matthew Blakeley
Imperial College London

Professor Karen Blyth
CRUK Scotland Institute

Cell death (apoptosis)

Dr Laura Martinez Escardo
CRUK Scotland Institute

Dr Juan M Jiménez Vacas
Institute of Cancer Research

Dr Kirsteen Campbell
CRUK Scotland Institute

Dr Adam Sharp
The Institute of Cancer
Research

Dr Andrea Mohr
University of Essex

Dr Asma Ahmed
University of Glasgow

RNA biology (processing, miRNA, non-coding RNA)

Miss Wanting Zeng
The Institute of Cancer
Research

Dr Claire Fletcher
Imperial College London

Professor Charlotte Bevan
Imperial College London

Dr Rayzel Fernandes
Imperial College London

Dr Damien Leach
Imperial College London

Mr Zu Ming Ng
Imperial College London

Miss Xinwei Zhou
Imperial College London

Radiobiology (radiotherapy, radionuclide therapy)

Dr Dechao Feng
University College London

Professor Duncan McLaren
Edinburgh Cancer Centre

Professor Jonathan Coulter
Queen's University Belfast

Professor Bill Nailon
NHS Lothian & University of
Edinburgh

Mr Eduardo Mota
University College London

Dr Kathy Chung Ying Chan
University of Oxford

Dr Alan McWilliam
The University of Manchester

Dr Jana McHugh
The Institute of Cancer
Research

Dr Tom Syer
University of Cambridge

Dr Alison Tree
The Royal Marsden NHS
Foundation Trust

Professor Emma Hall
The Institute of Cancer
Research

Dr Nikita Sushentsev
University of Cambridge

Dr Kim Reeves
The University of Manchester

Dr Md Rayhanul Islam
Queen's University Belfast

Professor Suneil Jain
Queen's University Belfast

Professor Ananya Choudhury
The University of Manchester

Dr Victoria Dunne
Queen's University Belfast

Dr Kang-Lung Lee
University of Cambridge

Surgery

Professor Greg Shaw
University College London
Hospital

Professor Imran Ahmad
University of Glasgow

Clinical translation (pre clinical trials)

Dr Joe Taylor
The Institute of Cancer Research

Dr Helen Pearson
Cardiff University

Dr Stephen Pennington
University College Dublin

Clinical trials (clinical trials, governance, blood sample management, late phase clinical trial management)

Mrs Penny Flohr
The Institute of Cancer
Research

Professor Gert Attard
University College London

Dr Eva Serrao
University of Cambridge

Professor Emma Hall
The Institute of Cancer
Research

Dr Valentine Macaulay
University of Oxford

Dr Peter Godolphin
MRC Clinical Trials Unit at
University College London

Professor Suneil Jain
Queen's University Belfast

Dr Mark Linch
University College London

Dr Srinivasa Rao
University of Oxford

Professor Johann de Bono
The Institute of Cancer
Research

Professor Robert Bristow
Manchester Cancer
Research Centre

Professor Greg Shaw
University College London
Hospital

Dr Alison Tree
The Royal Marsden NHS
Foundation Trust

Ms Sue Powell
Imperial College London

Imaging (acquisition, collection, processing, quality, MRI, PSMA-PET)

Dr Daniel Turnham
Cardiff University

Dr Jane Shortall
The University of
Manchester

Mr Omar El-Taji
The Christie, Manchester

Dr Ashwin Sachdeva
The University of
Manchester

Dr Mick Brown
The University of
Manchester

Professor Ananya Choudhury
The University of
Manchester

Professor Bill Nailon
NHS Lothian & University of
Edinburgh

Dr Alan McWilliam
The University of
Manchester

Dr Struan Gray
The Christie

Dr Donal McSweeney
The University of
Manchester

Ms Zhuolin Yang
Institute of Genetics and
Cancer, The University of
Edinburgh

Dr Shonit Punwani
University College London

Dr Amreen Shakur
Cambridge University
Hospitals Trust

Dr Tristan Barrett
University of Cambridge

Dr Veeru Kasivisvanathan
University College London

Dr Alexander Ng
University College London

Systematic reviews, meta-analysis and statistics

Professor Jayne Tierney
MRC Clinical Trials Unit at
University College London

Ms Larysa Rydzewska
MRC Clinical Trials Unit at
University College London

Dr Peter Godolphin
MRC Clinical Trials Unit at
University College London

Artificial intelligence, machine learning, big data

Professor Duncan McLaren
Edinburgh Cancer Centre

Dr Donal McSweeney
The University of
Manchester

Miss Sarah Elliot
University of Edinburgh

Dr Amreen Shakur
Cambridge University
Hospital's Trust

Dr Tristan Barrett
University of Cambridge

Professor Clare Verrill
University of Oxford

Professor Bill Nailon
NHS Lothian & University of
Edinburgh

Dr Shonit Punwani
University College London

Dr Kang-Lung Lee
Cambridge University

Dr Tom Syer
University of Cambridge

Dr Alexander Ng
University College London

Dr Dougal Ferguson
The University of
Manchester

Ms Zhuolin Yang
The University of Edinburgh

Professor David Waugh
University of South Australia

Mr Junjie Chai
Barts Cancer Institute

Dr Rachel Lawrence
Barts Cancer Institute

Professor Peter Gardner
University of Manchester

Bioinformatics (including cloud genomics software)

Dr Mazlina Ismail
University College London
Cancer Institute

Dr George Seed
The Institute of Cancer
Research

Professor Daniel Brewer
University of East Anglia

Dr Nicola Annels
University of Surrey

Dr Abraham Gihawi
University of East Anglia

Dr Joe Taylor
The Institute of Cancer
Research

Miss Denisa Bogdan
The Institute of Cancer
Research

Dr Emma Lishman-Walker
Newcastle University

Dr Sara Luzzi
Newcastle University

Dr Dechao Feng
University College London

Dr Simon McDade
Queens University Belfast

Data science (systematic review, meta-analysis, evidence synthesis)

Dr George Seed
The Institute of Cancer
Research

Ms Larysa Rydzewska
MRC Clinical Trials Unit at
University College London

Dr Tom Syer
University of Cambridge

Dr Claire Vale
MRC Clinical Trials Unit at
University College London

Ms Sarah Burdett
MRC Clinical Trials Unit at
University College London

Dr Peter Godolphin
MRC Clinical Trials Unit at
University College London

Dr Ashwin Sachdeva
University of Manchester

Outcome modelling

Dr Donal McSweeney
The University of Manchester

Dr Alan McWilliam
The University of Manchester

Drug development (fragment based drug discovery, protacs, medicinal chemistry, resistance, side effects)

Ms Ellen Olden
Imperial College London

Dr Jun Ishihara
Imperial College London

Dr Adam Sharp
The Institute of Cancer
Research

Miss Dominika Daremiak
Imperial College London

Dr Chun Fui Lai
Imperial College London

Miss Jessica Willis
Swansea University

Professor John Spencer
University of Sussex

Professor Simon Mackay
University of Strathclyde

Mr Kyle Greenland
Imperial College London

Miss Ziqian Peng
Newcastle University

Dr Rayzel Fernandes
Imperial College London

Dr Struan Gray
The Christie

Dr Paris Avgoustou
University of Sheffield

Dr Ameera Jailani
University of Sheffield

Nanotechnology (nanotherapy, nanoparticles)

Mr Nicolas Zeitouni
Imperial College London

Dr Md Rayhanul Islam
Queen's University Belfast

Professor Jonathan Coulter
Queen's University Belfast

Dr Hanieh Montaseri
Imperial College London

Immunology

Dr Ed Roberts
CRUK Scotland Institute

Dr Mark Linch
University College London

Dr Srinivasa Rao
University of Oxford

Dr Emma Scott
Newcastle University

Miss Poppy Brown
CRUK Scotland Institute

Miss Jinseon Kim
University of Oxford

Dr Jun Ishihara
Imperial College London

Professor Hardev Pandha
University of Surrey

Dr Kathy Chung Ying Chan
University of Oxford

Dr Asma Ahmed
University of Glasgow

Biomarkers

Dr Haiyan An
Swansea University

Miss Ziqian Peng
Newcastle University

Professor Suneil Jain
Queen's University Belfast

Dr Kim Reeves
The University of Manchester

Professor Daniel Brewer
University of East Anglia

Dr Stephen Pennington
University College Dublin

Professor Ananya Choudhury
The University of Manchester

Dr Conrado Guerrero Quiles
The University of Manchester

Ms Edwina Burke
Barts Cancer Institute

Professor Hing Leung
University of Glasgow

Liquid biopsies

Professor Yong-Jie Lu
Queen Mary University of
London

Miss Sarah McCarley
Queen Mary University of
London

Mrs Penny Flohr
The Institute of Cancer
Research

Ms Edwina Burke
Queen Mary University of
London

Miss Denisa Bogdan
The Institute of Cancer
Research

Prostate cancer

Mr Eduardo Mota
University College London

Miss Dominika Daremiak
Imperial College London

Mr Vithurran Thavarajah
University College London

Professor Johann de Bono
The Institute of Cancer
Research

Dr Uzoamaka Okoli
University College London

Neuroendocrine prostate cancer

Dr Zoe Maylin
Vancouver Prostate Centre

Professor Hardev Pandha
University of Surrey

Dr Francesco Crea
The Open University

Treatment (combination strategies, early disease, mesenchymal stem cell-based therapies, resistance, precision medicine)

Dr Hanieh Montaseri
Imperial College London

Dr Esther Baena
CRUK Manchester Institute

Professor Jason Carroll
University of Cambridge

Ms Ellen Olden
Imperial College London

Dr Andrea Mohr
University of Essex

Dr Francesco Crea
The Open University

Dr Juan M Jiménez Vacas
The Institute of Cancer
Research

Dr Ralf Zwacka
University of Essex

Dr Richa Vasani
University of Glasgow

Dr Qizhi Huang
University of Sheffield

Dr Adriana Buskin
Newcastle University

Metastasis (bone health, bone biology, exercise)

Dr Qizhi Huang
University of Sheffield

Dr Kirsty Hodgson
Newcastle University

Miss Yuhan Zhou
University of Sheffield

Dr Mick Brown
The University of
Manchester

Ms Edwina Burke
Barts Cancer Institute

Dr Ning Wang
University of Leicester

Ms Sarah Burdett
MRC Clinical Trials Unit at
University College London

Cancer disparities

Dr Susan Heavey
University College London

Professor Moray Campbell
Cedars-Sinai Medical Center

Dr Qizhi Huang
University of Sheffield

Oncology

Dr Miguel Reis Ferreira
King's College London

Miss Poppy Brown
CRUK Scotland Institute

Extracurricular (applying for funding, collaborations, consortium leadership, fellowships, managing a team, writing, starting a lab)

Dr Eileen Parkes
University of Oxford

Professor Johann de Bono
The Institute of Cancer
Research

Dr Benjamin Schumann
Imperial College London,
Francis Crick Institute

Professor Moray Campbell
Cedars-Sinai Medical Center

Professor Jayne Tierney
MRC Clinical Trials Unit at
University College London

Mr Rodhan Patke
University of Nottingham

Dr Stephen Pennington
University College Dublin

Professor Charlotte Bevan
Imperial College London

Professor Karen Blyth
CRUK Scotland Institute

Dr Kelly Coffey
Newcastle University

Dr Valentine Macaulay
University of Oxford

Dr Demi Pritchard
Swansea University

Dr Claire Fletcher
Imperial College London

Professor Paula Mendes
University of Birmingham

Dr Jason Webber
Swansea University

Professor Nigel Mongan
University of Nottingham


Ms Maggie Orozco Moreno
Newcastle University

Dr Rachel Barker
University of Bristol

Professor Ian Mills
University of Oxford

THANK YOU!

We can't wait to see you at the event.



**PROSTATE
CANCER UK**